![Trastuzumab deruxtecan in HER2+ gastric cancer overviewed by Arndt Vogel](https://oncodaily.com/pub/uploads/2024/04/download-122-e1717679147162.jpg)
Photo taken from Arndt Vogel/X
May 17, 2024, 16:09
Trastuzumab deruxtecan in HER2+ gastric cancer overviewed by Arndt Vogel
Arndt Vogel, managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, shared a post on X:
“Trastuzumab deruxtecan in HER2+ gastric cancer
exploratory biomarker analysis of DESTINY Gastric01
64% concordance btw HER2+ IHC and blood
MET, EGFR and FGFR2 GA: ORR low
HER2 mutations: ORR high
activity in Her2 low.”
Read further.
Source: Arndt Vogel/X